Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Weiß Elisabeth) > Multicenter prospec...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		05394naa a2200661 4500
001		oai:lup.lub.lu.se:156fab3c-b199-42d0-9da6-f4ad1bdf4537
003		SwePub
008		230130s2023 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
009		oai:prod.swepub.kib.ki.se:151326630
024	7	a https://lup.lub.lu.se/record/156fab3c-b199-42d0-9da6-f4ad1bdf45372 URI
024	7	a https://doi.org/10.1002/cyto.b.221052 DOI
024	7	a http://kipublications.ki.se/Default.aspx?queryparsed=id:1513266302 URI
040		a (SwePub)lud (SwePub)ki
041		a engb eng
042		9 SwePub
072	7	a art2 swepub-publicationtype
072	7	a ref2 swepub-contenttype
100	1	a Kern, Wolfgangu Munich Leukemia Laboratory (MLL)4 aut
245	1 0	a Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group
264		c 2022-11-23
264	1	b Wiley,c 2023
300		a 15 s.
520		a Background: Myelodysplastic syndromes (MDS) represent a diagnostic challenge. This prospective multicenter study was conducted to evaluate pre-defined flow cytometric markers in the diagnostic work-up of MDS and chronic myelomonocytic leukemia (CMML). Methods: Thousand six hundred and eighty-two patients with suspected MDS/CMML were analyzed by both cytomorphology according to WHO 2016 criteria and flow cytometry according to ELN recommendations. Flow cytometric readout was categorized ‘non-MDS’ (i.e. no signs of MDS/CMML and limited signs of MDS/CMML) and ‘in agreement with MDS’ (i.e., in agreement with MDS/CMML). Results: Flow cytometric readout categorized 60% of patients in agreement with MDS, 28% showed limited signs of MDS and 12% had no signs of MDS. In 81% of cases flow cytometric readouts and cytomorphologic diagnosis correlated. For high-risk MDS, the level of concordance was 92%. A total of 17 immunophenotypic aberrancies were found independently related to MDS/CMML in ≥1 of the subgroups of low-risk MDS, high-risk MDS, CMML. A cut-off of ≥3 of these aberrancies resulted in 80% agreement with cytomorphology (20% cases concordantly negative, 60% positive). Moreover, >3% myeloid progenitor cells were significantly associated with MDS (286/293 such cases, 98%). Conclusion: Data from this prospective multicenter study led to recognition of 17 immunophenotypic markers allowing to identify cases ‘in agreement with MDS’. Moreover, data emphasizes the clinical utility of immunophenotyping in MDS diagnostics, given the high concordance between cytomorphology and the flow cytometric readout. Results from the current study challenge the application of the cytomorphologically defined cut-off of 5% blasts for flow cytometry and rather suggest a 3% cut-off for the latter.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
653		a flow cytometry
653		a hematology
653		a multiparameter analysis
653		a myelodysplastic syndrome
700	1	a Westers, Theresia M.u Amsterdam UMC - Vrije Universiteit Amsterdam4 aut
700	1	a Bellos, Fraukeu Munich Leukemia Laboratory (MLL)4 aut
700	1	a Bene, Marie Christineu Nantes University Hospital4 aut
700	1	a Bettelheim, Peteru Elisabethinen Hospital Linz4 aut
700	1	a Brodersen, Lisa Eidenschinku Hematologics Inc.4 aut
700	1	a Burbury, Kateu Peter MacCallum Cancer Centre4 aut
700	1	a Chu, Sung Chao4 aut
700	1	a Cullen, Matthewu St James's University Hospital4 aut
700	1	a Porta, Matteo Dellau Humanitas Research Hospital4 aut
700	1	a Dunlop, Alan Stewartu UCL Cancer Institute4 aut
700	1	a Johansson, Ulrikau University Hospitals Bristol NHS Foundation Trust4 aut
700	1	a Matarraz, Sergiou University of Salamanca4 aut
700	1	a Oelschlaegel, Utau Dresden University of Technology4 aut
700	1	a Ogata, Kiyoyuki4 aut
700	1	a Porwit, Annau Lund University,Lunds universitet,Patologi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Pathology, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)an6742po
700	1	a Preijers, Franku Radboud University Medical Center4 aut
700	1	a Psarra, Katherinau Evangelismos Athens General Hospital4 aut
700	1	a Saft, Leonieu Karolinska Institutet,Karolinska University Hospital4 aut
700	1	a Subirá, Doloresu Hospital Universitario de Guadalajara4 aut
700	1	a Weiß, Elisabethu Munich Leukemia Laboratory (MLL)4 aut
700	1	a van der Velden, Vincent H.J.u Erasmus University Medical Center4 aut
700	1	a van de Loosdrecht, Arjanu Amsterdam UMC - Vrije Universiteit Amsterdam4 aut
700	1	a Weiss, E4 aut
710	2	a Munich Leukemia Laboratory (MLL)b Amsterdam UMC - Vrije Universiteit Amsterdam4 org
773	0	t Cytometry Part B - Clinical Cytometryd : Wileyg 104:1, s. 51-65q 104:1<51-65x 1552-4949x 1552-4957
856	4	u http://dx.doi.org/10.1002/cyto.b.22105y FULLTEXT
856	4 8	u https://lup.lub.lu.se/record/156fab3c-b199-42d0-9da6-f4ad1bdf4537
856	4 8	u https://doi.org/10.1002/cyto.b.22105
856	4 8	u http://kipublications.ki.se/Default.aspx?queryparsed=id:151326630

Hitta via bibliotek

Cytometry Part B - Clinical Cytometry (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Hematologi

Artiklar i publikationen: Cytometry Part B ...

Av lärosätet: Lunds universitet; Karolinska Institutet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se